Cyclazodone Stats & Data

• Class warning: Pemoline, a close structural relative, was withdrawn in the U.S. for risk of severe liver injury; cyclazodone’s human hepatotoxic risk is unquantified, so repeated or high‑dose use should be treated as potentially hepatotoxic. Discontinue and seek medical care if jaundice, right‑upper‑quadrant pain, dark urine, pale stools, or marked fatigue occur. • Consider baseline and periodic liver function tests (ALT/AST/bilirubin) if using beyond single occasional trials or more than once weekly; avoid if you have known liver disease. • Avoid stacking with hepatotoxins (heavy alcohol, high/repeated acetaminophen, anabolic steroids, isoniazid, high‑dose vitamin A) during the same week of use. • Onset can be variable; some users report very delayed or stepwise onsets and sudden intensity several hours later. Because of this, do not redose for several hours after an initial dose. • Cardiovascular screening and monitoring similar to other stimulants is prudent: avoid if you have uncontrolled hypertension, significant heart disease, or hyperthyroidism; check blood pressure/heart rate during first trials. • MAOIs are contraindicated with sympathomimetic stimulants due to hypertensive crises—do not combine within 14 days of MAOI use. • Combining with other stimulants or high caffeine increases risks of anxiety, tachycardia, hypertension, bruxism, and insomnia; spacing such agents is safer. • Subjective effects are often described as functional stimulation with focus and minimal euphoria; however, some users experience marked anxiety, body load, and dysphoria at doses others find moderate—start low, titrate cautiously. • Prefer oral administration; insufflation appears in anecdotes but offers no safety advantage and may increase adverse effects. • Product authenticity/purity is uncertain in gray markets; reagent references for cyclazodone are sparse. Where possible, use professional GC/MS drug checking; otherwise, avoid multi‑gram purchases and unknown vendors. • Tolerance to stimulation builds with frequent use; spacing use by several days reduces tolerance and cumulative strain on the liver and sleep. • There is no established human half‑life; effects are long enough that late‑day dosing can impair sleep. • Do not combine with decongestants (pseudoephedrine/phenylephrine) or other adrenergics due to additive pressor effects. • Avoid during pregnancy or if trying to conceive; there are no human safety data.